BiondVax Pharmaceuticals - ADR Peer Comparison

$0.69

$0.05 (7.81%)

As on 08-Nov-2023 09:30EDT

Market cap

$5 Mln

Revenue (TTM)

$2 Mln

P/E Ratio

--

P/B Ratio

7.5

Div. Yield

0 %

Edit

	BiondVax Pharmaceuticals - ADR	Zynerba Pharmaceuticals (ZYNE)
Market cap ($ Mln)	5	70
Revenue ($ Mln)	2	--
Net Profit ($ Mln)	17.22	-37.01
Net Margin (%)	854.38	49,625.92
RoE (%)	--	-98.36
Price to Earnings	--	--
Price-To-Book	7.48	0.54

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	BiondVax Pharmaceuticals - ADR	Zynerba Pharmaceuticals (ZYNE)
Operating Revenue	2.02	0.00
Cost of Revenue	0.00	0.00
Gross Profit	--	--
Operating Expenses	12.32	38.79
Operating Profit (EBIT)	-12.32	-38.79
Other Income	0.00	-0.07
Profit before Tax	-1.21	-37.58
Provision for Tax	-18.59	-0.93
Profit after Tax (Net Income)	17.22	-37.01
Minority Interest	0.00	0.00
Consolidated Profit	3.75	-19.45

Liabilities ($ Mln)

	BiondVax Pharmaceuticals - ADR	Zynerba Pharmaceuticals (ZYNE)
Shareholder's Funds	-7.11	29.02
Minority Interest	0.00	0.00
Non-Current Liabilities	25.12	0.00
Current Liabilities	1.89	11.46
Total Liabilities	27.07	55.52

Assets ($ Mln)

	BiondVax Pharmaceuticals - ADR	Zynerba Pharmaceuticals (ZYNE)
Non-Current Assets	12.13	1.18
Current Assets	7.77	39.29
Total Assets	27.07	55.52
Total Debt*	24.61	0.22
Net Current Assets	5.88	27.84

Cashflow ($ Mln)

	BiondVax Pharmaceuticals - ADR	Zynerba Pharmaceuticals (ZYNE)
Cash From Operating Activities	-7.27	-23.03
Cash Flow from Investing Activities	--	--
Cash from Financing Activities	6.78	6.01
Net Cash Inflow / Outflow	--	--

Ratios

Profitability Ratios

	BiondVax Pharmaceuticals - ADR	Zynerba Pharmaceuticals (ZYNE)
ROCE (%)	-0.94	-59.00
ROE (%)	-4.92	-98.36
ROA (%)	26.32	-57.62
EBIT Margin (%)	-618.44	--
Net Margin (%)	854.38	49,625.92
Cash Profit Margin (%)	0.00	--

Growth Ratios

	BiondVax Pharmaceuticals - ADR	Zynerba Pharmaceuticals (ZYNE)
Revenue Growth (%)	-26.64	--
EBIT Growth (%)	62.64	-5.13
Net Profit Growth (%)	141.72	2.64
EPS Growth (%)	--	16.03
Book Value Growth (%)	--	-58.14

Valuation Ratios

	BiondVax Pharmaceuticals - ADR	Zynerba Pharmaceuticals (ZYNE)
Price / Earnings	--	-0.69
Price / Book Value	--	0.52
Dividend Yield (%)	--	--
EV/EBITDA	-0.71	0.76
Market Cap ($ Cr)	--	--

Solvency Ratios

	BiondVax Pharmaceuticals - ADR	Zynerba Pharmaceuticals (ZYNE)
Debt to Equity	-3.28	0.00
Short term debt to equity ratio	-0.06	0.01
Current Ratio	4.12	3.43
Quick Ratio	4.12	3.31
Interest Coverage	0.93	-25.05

Operating Efficiency Ratios

	BiondVax Pharmaceuticals - ADR	Zynerba Pharmaceuticals (ZYNE)
Debtors to sales (%)	6.85	--
Asset Turnover	0.03	0.00
Receivable days	--	--
Inventory Days	--	--
Payable days	--	--
Cash Conversion Cycle	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly